Advertisement

Clinical and Experimental Medicine

, Volume 19, Issue 4, pp 487–494 | Cite as

NK and NKT-like cells in granulomatous and fibrotic lung diseases

  • L BergantiniEmail author
  • P Cameli
  • M d’Alessandro
  • C Vagaggini
  • RM Refini
  • C Landi
  • MG Pieroni
  • M Spalletti
  • P Sestini
  • E Bargagli
Original Article

Abtract

Background The pathogenetic and regulatory roles of natural killer (NK) and natural killer T-like cells in interstitial lung diseases (ILDs), fibrotic and granulomatous of unknown etiology are unclear. Objectives Here we investigated NK and NKT-like cells in peripheral blood (PB) and Bronchoalveolar lavage (BAL) from patients with ILDs. Method 190 patients (94 male mean age 61 ± 14.3 years) and 8 controls undergoing bronchoscopy for ILD diagnostic work-up were enrolled consecutively; 115 patients sarcoidosis, 24 chronic fibrotic hypersensitivity pneumonitis and 43 patients other ILDs [32 idiopathic pulmonary fibrosis (IPF) and 11 non-specific interstitial pneumonia (NSIP)]. PB and BAL were processed by flow cytometry using monoclonal antibodies to differentiate NK and NKT-like cells. Results NK% in BAL was significantly different among ILDs (p = 0.02). Lower NK% was observed in BAL from sarcoidosis than other ILDs (p < 0.05). Similar findings were observed for NKT-like, whereas no differences were found for PB NK%. Difference of NK% was observed between BAL and PB in all groups (p < 0.001). Sarcoidosis patients reported the best area under the curve for NKT-like (AUC = 0.678, p = 0.0015) and NK cells (AUC = 0.61, p = 0.001). In the IPF-NSIP subgroup, NK% cell was inversely correlated with FVC% (r = − 0.34, p = 0.03) and DLCO% (r = − 0.47, p = 0.0044). Conclusions NK and NKT-like were expressed differently in BAL from patients with different ILD and were significantly depleted in sarcoidosis respect to other ILDs. This suggests that these cells may play a protective role in the pathogenesis of sarcoidosis.

Keywords

Natural killer cells Natural killer T-like cells Bronchoalveolar lavage Interstitial lung diseases 

Abbreviations

LFT

Lung function tests

BAL

Bronchoalveolar lavage

NK

Natural killer cells

NKT-like

Natural killer T-like cells

IPF

Idiopathic pulmonary fibrosis

NSIP

Non-specific interstitial pneumonia

cHP

Chronic fibrotic hypersensitivity pneumonitis

ILD

Interstitial lung diseases

FVC

Forced vital capacity

FEV1

Forced expiratory volume in the first second

DLco

Diffuse lung carbon monoxide

Notes

Author contributions

LB conducted the study. LB and PC helped to define the study objectives and to coordinate the study. LB, PC and Md performed the statistical analysis and interpreted the results, CL, RMR and MP collected the data, MS and CV performed experiment, LB, EB and PS wrote the first draft of the manuscript. All authors critically revised the manuscript and approved its final version.

Funding

The study was conducted at Siena University without funding sponsors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Local Ethics Committee C.E. A. V. S. E. (Code Number 180712) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10238_2019_578_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 18 kb)

References

  1. 1.
    O’Brien KL, Finlay DK. Immunometabolism and natural killer cell responses. Nat Rev Immunol. 2019;19(5):282–90.  https://doi.org/10.1038/s41577-019-0139-2.CrossRefPubMedGoogle Scholar
  2. 2.
    Wang X, Peng H, Tian Z. Innate lymphoid cell memory. Cell Mol Immunol. 2019;16(5):423–9.  https://doi.org/10.1038/s41423-019-0212-6.CrossRefPubMedGoogle Scholar
  3. 3.
    Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L, Human NK. Cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019;16(5):430–41.  https://doi.org/10.1038/s41423-019-0206-4.CrossRefPubMedGoogle Scholar
  4. 4.
    Jiang H-J, Wang X-X, Luo B-F, et al. Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients. Clin Exp Med. 2019;19(3):299–308.  https://doi.org/10.1007/s10238-019-00564-9.CrossRefPubMedGoogle Scholar
  5. 5.
    Parasa VR, Selvaraj A, Sikhamani R, Raja A. Interleukins 15 and 12 in combination expand the selective loss of natural killer T cells in HIV infection in vitro. Clin Exp Med. 2015;15(2):205–13.  https://doi.org/10.1007/s10238-014-0278-5.CrossRefPubMedGoogle Scholar
  6. 6.
    Shi TD, Zhang JM, Wang XF, et al. Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. Clin Exp Med. 2012;12(2):105–13.  https://doi.org/10.1007/s10238-011-0151-8.CrossRefPubMedGoogle Scholar
  7. 7.
    Yu JC, Lin G, Field JJ, Linden J. Induction of antiinflammatory purinergic signaling in activated human iNKT cells. JCI Insight. 2018.  https://doi.org/10.1172/jci.insight.91954.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Stankovic B, Bjørhovde HAK, Skarshaug R, et al. Immune cell composition in human non-small cell lung cancer. Front Immunol. 2018;9:3101.  https://doi.org/10.3389/fimmu.2018.03101.CrossRefPubMedGoogle Scholar
  9. 9.
    Eriksson Ström J, Pourazar J, Linder R, et al. Cytotoxic lymphocytes in COPD airways: increased NK cells associated with disease, iNKT and NKT-like cells with current smoking. Respir Res. 2018;19(1):244.  https://doi.org/10.1186/s12931-018-0940-7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Novak J, Novakova L. Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells. Clin Exp Med. 2013;13(4):229–37.  https://doi.org/10.1007/s10238-012-0199-0.CrossRefPubMedGoogle Scholar
  11. 11.
    Lin Y-L, Lin S-C. Analysis of the CD161-expressing cell quantities and CD161 expression levels in peripheral blood natural killer and T cells of systemic lupus erythematosus patients. Clin Exp Med. 2017;17(1):101–9.  https://doi.org/10.1007/s10238-015-0402-1.CrossRefPubMedGoogle Scholar
  12. 12.
    Grégoire C, Chasson L, Luci C, et al. The trafficking of natural killer cells. Immunol Rev. 2007;220:169–82.  https://doi.org/10.1111/j.1600-065X.2007.00563.x.CrossRefPubMedGoogle Scholar
  13. 13.
    Wang J, Li F, Zheng M, Sun R, Wei H, Tian Z. Lung natural killer cells in mice: phenotype and response to respiratory infection. Immunology. 2012;137(1):37–47.  https://doi.org/10.1111/j.1365-2567.2012.03607.x.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Riemann D, Cwikowski M, Turzer S, et al. Blood immune cell biomarkers in lung cancer. Clin Exp Immunol. 2019;195(2):179–89.  https://doi.org/10.1111/cei.13219.CrossRefPubMedGoogle Scholar
  15. 15.
    Hodge G, Hodge S. Therapeutic targeting steroid resistant pro-inflammatory NK and NKT-like cells in chronic inflammatory lung disease. Int J Mol Sci. 2019.  https://doi.org/10.3390/ijms20061511.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Harpur CM, Stankovic S, Kanagarajah A, et al. Enrichment of cytomegalovirus-induced NKG2C + natural killer cells in the lung allograft. Transplantation. 2018.  https://doi.org/10.1097/TP.0000000000002545.CrossRefGoogle Scholar
  17. 17.
    Calabrese DR, Lanier LL, Greenland JR. Natural killer cells in lung transplantation. Thorax. 2019;74(4):397–404.  https://doi.org/10.1136/thoraxjnl-2018-212345.CrossRefPubMedGoogle Scholar
  18. 18.
    Souza-Fonseca-Guimaraes P, Guimaraes F, Natânia De Souza-Araujo C, et al. Natural killer cell assessment in peripheral circulation and bronchoalveolar lavage fluid of patients with severe sepsis: a case control study. Int J Mol Sci. 2017;18(3):1–2.  https://doi.org/10.3390/ijms18030616.CrossRefGoogle Scholar
  19. 19.
    Paget C, Trottein F. Role of type 1 natural killer T cells in pulmonary immunity. Mucosal Immunol. 2013;6(6):1054–67.  https://doi.org/10.1038/mi.2013.59.CrossRefPubMedGoogle Scholar
  20. 20.
    Katchar K, Söderström K, Wahlstrom J, Eklund A, Grunewald J. Characterisation of natural killer cells and CD56 + T-cells in sarcoidosis patients. Eur Respir J. 2005;26(1):77–85.  https://doi.org/10.1183/09031936.05.00030805.CrossRefPubMedGoogle Scholar
  21. 21.
    Papanikolaou IC, Boki KA, Giamarellos-Bourboulis EJ, et al. Innate immunity alterations in idiopathic interstitial pneumonias and rheumatoid arthritis-associated interstitial lung diseases. Immunol Lett. 2015;163(2):179–86.  https://doi.org/10.1016/j.imlet.2014.12.004.CrossRefPubMedGoogle Scholar
  22. 22.
    Sokhatska O, Padrão E, Sousa-Pinto B, et al. NK and NKT cells in the diagnosis of diffuse lung diseases presenting with a lymphocytic alveolitis. BMC Pulm Med. 2019;19:1–2.  https://doi.org/10.1186/s12890-019-0802-1.CrossRefGoogle Scholar
  23. 23.
    Travis WD, Costabel U, Hansell DM, et al. An official american thoracic society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.  https://doi.org/10.1164/rccm.201308-1483ST.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American thoracic society/European respiratory society/World association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 1999;16(2):149–73.Google Scholar
  25. 25.
    Morisset J, Johannson KA, Jones KD, et al. Identification of diagnostic criteria for chronic hypersensitivity pneumonitis: an international modified delphi survey. Am J Respir Crit Care Med. 2018;197(8):1036–44.  https://doi.org/10.1164/rccm.201710-1986OC.CrossRefPubMedGoogle Scholar
  26. 26.
    Culver BH, Graham BL, Coates AL, et al. Recommendations for a standardized pulmonary function report. An official American thoracic society technical statement. Am J Respir Crit Care Med. 2017;196(11):1463–72.  https://doi.org/10.1164/rccm.201710-1981st.CrossRefPubMedGoogle Scholar
  27. 27.
    Meyer KC, Raghu G, Baughman RP, et al. An official American thoracic society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004–14.  https://doi.org/10.1164/rccm.201202-0320ST.CrossRefPubMedGoogle Scholar
  28. 28.
    Landi C, Bargagli E, Carleo A, et al. A functional proteomics approach to the comprehension of sarcoidosis. J Proteomics. 2015;128:375–87.  https://doi.org/10.1016/j.jprot.2015.08.012.CrossRefPubMedGoogle Scholar
  29. 29.
    Bergantini L, Bianchi F, Cameli P, et al. Prognostic biomarkers of sarcoidosis: a comparative study of serum chitotriosidase, ACE, Lysozyme, and KL-6. Dis Mark. 2019;2019:8565423.  https://doi.org/10.1155/2019/8565423.CrossRefGoogle Scholar
  30. 30.
    Bargagli E, Prasse A. Sarcoidosis: a review for the internist. Int Emerg Med. 2018;13(3):325–31.  https://doi.org/10.1007/s11739-017-1778-6.CrossRefGoogle Scholar
  31. 31.
    Lepzien R, Rankin G, Pourazar J, et al. Mapping mononuclear phagocytes in blood, lungs, and lymph nodes of sarcoidosis patients. J Leukoc Biol. 2019;105(4):797–807.  https://doi.org/10.1002/JLB.5A0718-280RR.CrossRefPubMedGoogle Scholar
  32. 32.
    Agostini C, Trentin L, Zambello R, et al. Phenotypical and functional analysis of natural killer cells in sarcoidosis. Clin Immunol Immunopathol. 1985;37(2):262–75.CrossRefPubMedGoogle Scholar
  33. 33.
    Rijavec M, Volarevic S, Osolnik K, Kosnik M, Korosec P. Natural killer T cells in pulmonary disorders. Respir Med. 2011;105(Suppl 1):S20–5.  https://doi.org/10.1016/S0954-6111(11)70006-3.CrossRefPubMedGoogle Scholar
  34. 34.
    Korosec P, Rijavec M, Silar M, Kern I, Kosnik M, Osolnik K. Deficiency of pulmonary Valpha24 Vbeta11 natural killer T cells in corticosteroid-naïve sarcoidosis patients. Respir Med. 2010;104(4):571–7.  https://doi.org/10.1016/j.rmed.2009.11.008.CrossRefPubMedGoogle Scholar
  35. 35.
    Temprano J, Becker BA, Hutcheson PS, Knutsen AP, Dixit A, Slavin RG. Hypersensitivity pneumonitis secondary to residential exposure to Aureobasidium pullulans in 2 siblings. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2007;99(6):562–6.  https://doi.org/10.1016/S1081-1206(10)60387-0.CrossRefGoogle Scholar
  36. 36.
    Nogueira R, Melo N, e Bastos HN, et al. Hypersensitivity pneumonitis: antigen diversity and disease implications. Pulmonology. 2019;25(2):97–108.  https://doi.org/10.1016/j.pulmoe.2018.07.003.CrossRefPubMedGoogle Scholar
  37. 37.
    Boyton R. The role of natural killer T cells in lung inflammation. J Pathol. 2008;214(2):276–82.  https://doi.org/10.1002/path.2290.CrossRefPubMedGoogle Scholar
  38. 38.
    Papakosta D, Manika K, Gounari E, et al. Bronchoalveolar lavage fluid and blood natural killer and natural killer T-like cells in cryptogenic organizing pneumonia. Respirol Carlton Vic. 2014;19(5):748–54.  https://doi.org/10.1111/resp.12305.CrossRefGoogle Scholar
  39. 39.
    Galati D, De Martino M, Trotta A, et al. Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis in idiopathic pulmonary fibrosis patients. Cytokine. 2014;66(2):119–26.  https://doi.org/10.1016/j.cyto.2013.12.003.CrossRefPubMedGoogle Scholar
  40. 40.
    Goh NS, Hoyles RK, Denton CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017;69(8):1670–8.  https://doi.org/10.1002/art.40130.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Respiratory Disease and Lung Transplant Unit, Department of Medical Sciences, Surgery and NeurosciencesSiena UniversitySienaItaly
  2. 2.Department of Life SciencesSiena UniversitySienaItaly

Personalised recommendations